Swiss National Bank cut its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 19.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 98,100 shares of the medical research company’s stock after selling 23,600 shares during the quarter. Swiss National Bank owned 0.12% of NeoGenomics worth $879,000 at the end of the most recent quarter.
Other hedge funds also recently made changes to their positions in the company. Cambridge Investment Research Advisors Inc. increased its stake in shares of NeoGenomics by 7.9% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 13,600 shares of the medical research company’s stock valued at $107,000 after acquiring an additional 1,000 shares during the last quarter. Wrapmanager Inc. bought a new stake in shares of NeoGenomics in the 2nd quarter valued at about $109,000. KCG Holdings Inc. bought a new stake in NeoGenomics during the 1st quarter worth approximately $118,000. OLD National Bancorp IN bought a new stake in NeoGenomics during the 2nd quarter worth approximately $141,000. Finally, Parkwood LLC bought a new stake in NeoGenomics during the 2nd quarter worth approximately $165,000. 80.41% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.dispatchtribunal.com/2017/10/28/neogenomics-inc-neo-position-cut-by-swiss-national-bank.html.
A number of research firms recently issued reports on NEO. Zacks Investment Research raised NeoGenomics from a “sell” rating to a “hold” rating in a research note on Thursday. Janney Montgomery Scott reissued a “buy” rating on shares of NeoGenomics in a research note on Thursday. BidaskClub cut NeoGenomics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 18th. ValuEngine raised NeoGenomics from a “sell” rating to a “hold” rating in a research note on Monday, August 7th. Finally, BTIG Research cut NeoGenomics from a “buy” rating to a “neutral” rating in a research note on Monday, September 11th. One analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $10.33.
NeoGenomics, Inc. (NASDAQ:NEO) opened at 8.49 on Friday. NeoGenomics, Inc. has a 52 week low of $7.12 and a 52 week high of $11.63. The company’s market capitalization is $674.00 million. The stock’s 50 day moving average is $10.38 and its 200 day moving average is $9.02.
NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Wednesday, October 25th. The medical research company reported $0.01 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.01. The firm had revenue of $63.05 million during the quarter, compared to the consensus estimate of $63.11 million. NeoGenomics had a positive return on equity of 3.98% and a negative net margin of 4.78%. The company’s quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.04 earnings per share. Analysts predict that NeoGenomics, Inc. will post $0.13 EPS for the current fiscal year.
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.